

# Provider Education

## Rebaselining of Autoimmune Testing



Effective April 22, 2026, Methodist Health System will transition select send-out autoimmune testing to be performed at Methodist Jennie Edmundson utilizing the Thermo Fisher Phadia platform. It is recommended to rebase patients who are monitored through the following tests: tTg IgA Antibody, MPO IgG Antibody, and PR3 IgG Antibody. Additionally, for serial antiphospholipid syndrome (APS) testing, all APS tests that were initially started at ARUP will continue to be performed with the same methodology at ARUP.

Providers may order the new test(s) listed below. If prior testing was performed at ARUP, laboratory staff will place the appropriate ARUP send-out order. Patients will not be billed for ARUP testing.

The rebaselining period varies by test; please refer to the chart below for detailed information.

New MHS Test Orderable	Added ARUP Test Code	End of Rebaselining
Myeloperoxidase IgG Antibody	0050526	October 22 <sup>nd</sup> , 2026
PR3 IgG Antibody	0050527	October 22 <sup>nd</sup> , 2026
Tissue Transglutaminase IgA	3016860	April 22 <sup>nd</sup> , 2027

Both results will be documented in the patient record. A comment will be added to the MHS test orderable stating: "Test result represents new methodology implemented April 22, 2026."

After the rebaselining period has concluded, rebase testing may still be ordered at the provider's discretion upon request.

For questions or further clarification, please contact Dr. Becki Kahn, Ashley Taylor or Tia Brandenburg at 712-396-6311.